Altimmune, Inc. (NASDAQ:ALT) Receives $16.60 Average Target Price from Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $16.60.

Several research firms have issued reports on ALT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Citizens Jmp decreased their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Monday, October 20th.

Altimmune Stock Performance

Shares of Altimmune stock opened at $4.24 on Friday. The firm has a market capitalization of $442.40 million, a P/E ratio of -3.96 and a beta of 0.04. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08. The company has a 50 day moving average price of $4.51 and a 200 day moving average price of $4.10. Altimmune has a 52 week low of $2.90 and a 52 week high of $7.73.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. Sell-side analysts expect that Altimmune will post -1.35 EPS for the current year.

Insiders Place Their Bets

In other Altimmune news, Director Jerome Benedict Durso acquired 12,500 shares of the stock in a transaction dated Monday, December 22nd. The shares were bought at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,625. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Gill purchased 12,500 shares of the business’s stock in a transaction on Tuesday, December 23rd. The shares were acquired at an average cost of $4.10 per share, with a total value of $51,250.00. Following the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $51,250. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 30,527 shares of company stock valued at $125,278. Company insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after buying an additional 2,241 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Altimmune in the 1st quarter worth $50,000. Baader Bank Aktiengesellschaft bought a new position in shares of Altimmune in the second quarter worth about $133,000. Wealth Enhancement Advisory Services LLC raised its stake in Altimmune by 70.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 24,828 shares of the company’s stock worth $96,000 after buying an additional 10,264 shares in the last quarter. Finally, Keudell Morrison Wealth Management acquired a new stake in shares of Altimmune in the 2nd quarter worth $63,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.